Grifols (GIFLF) Invested Capital (2009 - 2025)
Grifols' (GIFLF) quarterly Invested Capital came in at $16.7 billion in Q4 2025, down 2.52% on a YoY basis from $17.2 billion in Q4 2024, and down 2.52% quarter-over-quarter from $17.2 billion in Q4 2024.
Analysis
Grifols (GIFLF) Invested Capital (2009 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Invested Capital for 17 consecutive years, with $16.7 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Invested Capital fell 2.52% year-over-year to $16.7 billion; the trailing twelve-month figure through Dec 2025 stood at $16.7 billion (down 2.52% YoY), and the FY2025 full-year result was $16.2 billion, down 5.39% from the prior year.
- Invested Capital retreated to $16.7 billion in Q4 2025 per GIFLF's latest filing, from $17.2 billion in the prior quarter.
- Across five years, Invested Capital topped out at $20.0 billion in Q4 2023 and bottomed at $16.7 billion in Q4 2025.
- Historically, Invested Capital has averaged $18.5 billion across 5 years, with a median of $19.2 billion in 2022.
- The sharpest annual moves came in 2021 and 2024: Invested Capital increased 19.11% in 2021, then retreated 14.16% in 2024.
- Over 5 years, Invested Capital stood at $19.5 billion in 2021, then slipped by 1.51% to $19.2 billion in 2022, then gained by 3.91% to $20.0 billion in 2023, then decreased by 14.16% to $17.2 billion in 2024, then decreased by 2.52% to $16.7 billion in 2025.
- According to Business Quant data, Invested Capital over the past three periods registered $16.7 billion, $17.2 billion, and $20.0 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 74.44 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 40.49 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 33.70 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 7.35 Bn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 26.94 Bn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 16.72 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 16.72 Bn |
| Dec 31, 2024 | 17.15 Bn |
| Dec 31, 2023 | 19.98 Bn |
| Dec 31, 2022 | 19.23 Bn |
| Dec 31, 2021 | 19.52 Bn |
| Dec 31, 2020 | 16.39 Bn |
| Sep 30, 2020 | 16.54 Bn |
| Mar 31, 2020 | 15.90 Bn |
| Dec 31, 2019 | 15.56 Bn |
| Sep 30, 2019 | 14.03 Bn |
| Dec 31, 2018 | 12.64 Bn |
| Sep 30, 2018 | 12.23 Bn |
| Jun 30, 2018 | 12.17 Bn |
| Mar 31, 2018 | 14.83 Bn |
| Dec 31, 2017 | 11.41 Bn |
| Jun 30, 2017 | 10.74 Bn |
| Dec 31, 2016 | 9.35 Bn |
| Sep 30, 2016 | 9.20 Bn |
| Jun 30, 2016 | 9.19 Bn |
| Mar 31, 2016 | 8.52 Bn |